Rhythm Pharmaceuticals (NASDAQ:RYTM) Downgraded by Zacks Investment Research to “Hold”

Share on StockTwits

Rhythm Pharmaceuticals (NASDAQ:RYTM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company’s product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA. “

Other equities analysts also recently issued reports about the company. Cowen reaffirmed a “buy” rating and set a $40.00 price target on shares of Rhythm Pharmaceuticals in a research report on Wednesday, September 25th. BidaskClub upgraded Rhythm Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 22nd. Finally, LADENBURG THALM/SH SH reissued a “buy” rating and issued a $43.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Monday, September 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. Rhythm Pharmaceuticals has an average rating of “Buy” and a consensus price target of $38.80.

Shares of Rhythm Pharmaceuticals stock remained flat at $$22.40 on Wednesday. 93,611 shares of the stock were exchanged, compared to its average volume of 244,924. The firm’s 50-day moving average price is $21.86 and its 200 day moving average price is $22.14. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.02. Rhythm Pharmaceuticals has a 52-week low of $18.00 and a 52-week high of $31.94. The stock has a market cap of $986.15 million, a PE ratio of -9.37 and a beta of 0.66.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its earnings results on Friday, November 1st. The company reported ($1.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.06) by $0.02. As a group, equities research analysts anticipate that Rhythm Pharmaceuticals will post -4 earnings per share for the current year.

In other Rhythm Pharmaceuticals news, Director Todd Foley sold 25,366 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $22.03, for a total transaction of $558,812.98. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 444,075 shares of company stock valued at $9,935,520 over the last quarter. 4.45% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC acquired a new position in shares of Rhythm Pharmaceuticals in the third quarter valued at about $1,547,000. DekaBank Deutsche Girozentrale purchased a new position in Rhythm Pharmaceuticals during the 2nd quarter worth approximately $564,000. Susquehanna International Group LLP purchased a new position in Rhythm Pharmaceuticals during the 2nd quarter worth approximately $328,000. Rice Hall James & Associates LLC raised its position in Rhythm Pharmaceuticals by 172.5% during the 2nd quarter. Rice Hall James & Associates LLC now owns 63,217 shares of the company’s stock worth $1,391,000 after buying an additional 40,015 shares during the last quarter. Finally, Fosun International Ltd lifted its stake in Rhythm Pharmaceuticals by 37.0% during the 2nd quarter. Fosun International Ltd now owns 40,720 shares of the company’s stock valued at $883,000 after acquiring an additional 11,000 shares during the period. 78.13% of the stock is owned by institutional investors.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.

Featured Article: What is the Dividend Aristocrat Index?

Get a free copy of the Zacks research report on Rhythm Pharmaceuticals (RYTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Rhythm Pharmaceuticals  Downgraded by Zacks Investment Research to “Hold”
Rhythm Pharmaceuticals Downgraded by Zacks Investment Research to “Hold”
Lands’ End  Trading 1.2% Higher  After Strong Earnings
Lands’ End Trading 1.2% Higher After Strong Earnings
Software AG  Given Consensus Recommendation of “Hold” by Analysts
Software AG Given Consensus Recommendation of “Hold” by Analysts
TOP Price Tops $0.0016 on Top Exchanges
TOP Price Tops $0.0016 on Top Exchanges
Swing  Trading Down 17.6% Over Last 7 Days
Swing Trading Down 17.6% Over Last 7 Days
TrustNote One Day Volume Reaches $6.00
TrustNote One Day Volume Reaches $6.00


© 2006-2019 Ticker Report